<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01323205</url>
  </required_header>
  <id_info>
    <org_study_id>CR018340</org_study_id>
    <secondary_id>40411813SCH2001</secondary_id>
    <secondary_id>2010-023369-23</secondary_id>
    <nct_id>NCT01323205</nct_id>
  </id_info>
  <brief_title>Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia</brief_title>
  <official_title>First-in-Patient Study to Assess the Safety and Tolerability and to Explore the Potential Therapeutic Efficacy of a Novel Glutamate Modulator as Monotherapy and as Add-On Therapy in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the safety, tolerability, and potential clinical
      efficacy of JNJ 40411813 in schizophrenic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human study of JNJ-40411813 in schizophrenic patients who are not
      currently receiving antipsychotic drug treatment (referred to as &quot;(sub) acute&quot; patients) and
      in patients who are currently taking antipsychotic drug treatment (referred to as &quot;stable&quot;
      patients). The study will consist of 2 parts: Part A and Part B. Part A will be open-label
      (patients will know the identity of study treatment), and (sub)acute schizophrenic patients
      will receive monotherapy (treatment with one drug) with JNJ-40411813. Part B will be
      double-blind (patient and study staff will not know the identity of study treatment) and will
      randomize (assign by chance) patients with stable but symptomatic schizophrenia to receive
      treatment with JNJ-40411813 or a placebo (treatment identical in appearance to JNJ-40411813
      but does not contain active drug) as add-on therapy to their currently prescribed
      antipsychotic medication. Parts A (JNJ-40411813 monotherapy) and B (JNJ-40411813 add-on
      therapy) will run simultaneously. Patients will take JNJ-40411813 and placebo capsules orally
      (by mouth) twice daily (bid) with a meal. Part A: Patients will take JNJ-40411813 50 mg (1
      capsule) bid up to 150 mg (3 capsules) bid for up to 12 weeks. Part B: Patients will take
      JNJ-40411813 50 mg bid or placebo bid for 4 weeks. After 4 weeks, the dose of JNJ-40411813
      may be increased up to 150 mg bid for 6 weeks, and patients assigned to placebo may take
      JNJ-40411813 50 mg bid to 150 mg bid for up to 10 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Udvalg for Klinische Undersogelser (UKU) ratings for side effects reported by patients</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of patients with abnormal results from clinical laboratory tests performed as a measure of safety and tolerability</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of patients with abnormal results from electrocardiograms (ECGs) performed as a measure of safety and tolerability</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of patients with abnormal results from physical examinations (including vital signs measurements) performed as a measure of safety and tolerability</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events reported as a measure of safety and tolerability</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS) scores to explore potential therapeutic effect of study drug</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Schizophrenia (CGI-SCH) ratings to explore potential therapeutic effect of study drug</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Well-being under Neuroleptics Scale (SWN) scores to explore potential therapeutic effect of study drug</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma (blood) concentration of JNJ-40411813</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>JNJ-40411813 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JNJ-40411813 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and JNJ-40411813 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo capsule (s) orally twice daily with a meal for 4 weeks followed by JNJ-40411813 according to tolerability dose range increased from 50 mg to 150 mg twice daily with a meal to 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-40411813</intervention_name>
    <description>JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 12 weeks.</description>
    <arm_group_label>JNJ-40411813 (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-40411813</intervention_name>
    <description>JNJ-40411813 starting dose from 50 to 150 mg as an add-on therapy. Dose is increased step-wise from 50 mg to 150 mg. Capsule(s) taken by mouth twice daily with a meal for 10 weeks.</description>
    <arm_group_label>JNJ-40411813 (Part B)</arm_group_label>
    <arm_group_label>Placebo and JNJ-40411813 (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule (s) orally twice daily with a meal for 4 weeks.</description>
    <arm_group_label>Placebo and JNJ-40411813 (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antipsychotic medication</intervention_name>
    <description>Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol Hydrochloride, Clotiapine, Pipamperone Hydrochloride, Benperidol, Flupentixol, Fluphenazine Decanoate, Melperone Hydrochloride, or Chlorpromazine Hydrochloride) will be continued in Part B.</description>
    <arm_group_label>JNJ-40411813 (Part B)</arm_group_label>
    <arm_group_label>Placebo and JNJ-40411813 (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) between 18 and 35 kg/m2 inclusive

          -  Medically stable on the basis of physical examination, medical history, vital signs,
             12-lead ECG and clinical laboratory tests

          -  In- or outpatients who have been diagnosed with schizophrenia according to Diagnostic
             and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) at least 1 year
             prior to screening.

        Exclusion Criteria:

          -  A current DSM-IV axis I diagnosis other than schizophrenia

          -  Any medical condition that could potentially alter the absorption, metabolism, or
             excretion of the study medication, such as Crohn's disease, liver disease, or renal
             disease

          -  Relevant history of any significant and/or unstable cardiovascular, respiratory,
             neurologic (including seizures or significant cerebrovascular disorders), renal,
             hepatic, endocrine, or immunologic diseases

          -  PANSS score &lt;50 or &gt;120

          -  Other significant and/or unstable systemic illnesses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dave</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duffel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kortenberg</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lede</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Radnevo N/A</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>MÃ¼nchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arad</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zamora</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Romania</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2011</study_first_submitted>
  <study_first_submitted_qc>March 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2011</study_first_posted>
  <disposition_first_submitted>November 15, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>November 15, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 10, 2013</disposition_first_posted>
  <last_update_submitted>May 22, 2014</last_update_submitted>
  <last_update_submitted_qc>May 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>JNJ-40411813</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

